Literature DB >> 27130831

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.

Pavel A Levin1, Rolf A Brekken1, Lauren Averett Byers2, John V Heymach2, David E Gerber3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27130831      PMCID： PMC4961571          DOI： 10.1016/j.jtho.2016.04.015

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  35 in total

Review 1.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

Review 2.  The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Authors:  Douglas K Graham; Deborah DeRyckere; Kurtis D Davies; H Shelton Earp
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

3.  An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo.

Authors:  Manikandan Subramanian; Crystal D Hayes; Joseph J Thome; Edward Thorp; Glenn K Matsushima; Joachim Herz; Donna L Farber; Kang Liu; Madepalli Lakshmana; Ira Tabas
Journal:  J Clin Invest       Date:  2014-02-10       Impact factor: 14.808

4.  The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.

Authors:  Fang Wu; Junhe Li; Changchen Jang; Janfeng Wang; Jianping Xiong
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

Authors:  Amanda Kirane; Kathleen F Ludwig; Noah Sorrelle; Gry Haaland; Tone Sandal; Renate Ranaweera; Jason E Toombs; Miao Wang; Sean P Dineen; David Micklem; Michael T Dellinger; James B Lorens; Rolf A Brekken
Journal:  Cancer Res       Date:  2015-07-23       Impact factor: 12.701

6.  Determinants for transformation induced by the Axl receptor tyrosine kinase.

Authors:  A Burchert; E C Attar; P McCloskey; Y W Fridell; E T Liu
Journal:  Oncogene       Date:  1998-06-18       Impact factor: 9.867

Review 7.  AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.

Authors:  Samuel H Myers; Valerie G Brunton; Asier Unciti-Broceta
Journal:  J Med Chem       Date:  2015-11-20       Impact factor: 7.446

8.  AXL mediates resistance to cetuximab therapy.

Authors:  Toni M Brand; Mari Iida; Andrew P Stein; Kelsey L Corrigan; Cara M Braverman; Neha Luthar; Mahmoud Toulany; Parkash S Gill; Ravi Salgia; Randall J Kimple; Deric L Wheeler
Journal:  Cancer Res       Date:  2014-08-18       Impact factor: 12.701

9.  Targeting Axl with an high-affinity inhibitory aptamer.

Authors:  Laura Cerchia; Carla L Esposito; Simona Camorani; Anna Rienzo; Loredana Stasio; Luigi Insabato; Andrea Affuso; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

10.  The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.

Authors:  Magdalena Paolino; Axel Choidas; Stephanie Wallner; Blanka Pranjic; Iris Uribesalgo; Stefanie Loeser; Amanda M Jamieson; Wallace Y Langdon; Fumiyo Ikeda; Juan Pablo Fededa; Shane J Cronin; Roberto Nitsch; Carsten Schultz-Fademrecht; Jan Eickhoff; Sascha Menninger; Anke Unger; Robert Torka; Thomas Gruber; Reinhard Hinterleitner; Gottfried Baier; Dominik Wolf; Axel Ullrich; Bert M Klebl; Josef M Penninger
Journal:  Nature       Date:  2014-02-19       Impact factor: 49.962
View more
  14 in total

1.  Function of Axl receptor tyrosine kinase in non-small cell lung cancer.

Authors:  Guoan Zhang; Meng Wang; Hongli Zhao; Wen Cui
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

2.  Institutional implementation of clinical tumor profiling on an unselected cancer population.

Authors:  Lynette M Sholl; Khanh Do; Priyanka Shivdasani; Ethan Cerami; Adrian M Dubuc; Frank C Kuo; Elizabeth P Garcia; Yonghui Jia; Phani Davineni; Ryan P Abo; Trevor J Pugh; Paul van Hummelen; Aaron R Thorner; Matthew Ducar; Alice H Berger; Mizuki Nishino; Katherine A Janeway; Alanna Church; Marian Harris; Lauren L Ritterhouse; Joshua D Campbell; Vanesa Rojas-Rudilla; Azra H Ligon; Shakti Ramkissoon; James M Cleary; Ursula Matulonis; Geoffrey R Oxnard; Richard Chao; Vanessa Tassell; James Christensen; William C Hahn; Philip W Kantoff; David J Kwiatkowski; Bruce E Johnson; Matthew Meyerson; Levi A Garraway; Geoffrey I Shapiro; Barrett J Rollins; Neal I Lindeman; Laura E MacConaill
Journal:  JCI Insight       Date:  2016-11-17

Review 3.  Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.

Authors:  Triparna Sen; Carl M Gay; Lauren Averett Byers
Journal:  Transl Lung Cancer Res       Date:  2018-02

4.  The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors.

Authors:  Sarah Saab; Olin Shih-Shin Chang; Kentaro Nagaoka; Mien-Chie Hung; Hirohito Yamaguchi
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

Review 5.  Role of ELMO1 in inflammation and cancer-clinical implications.

Authors:  Stefania Tocci; Stella-Rita Ibeawuchi; Soumita Das; Ibrahim M Sayed
Journal:  Cell Oncol (Dordr)       Date:  2022-06-06       Impact factor: 7.051

6.  FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma.

Authors:  Mariana Cooke; Gabriel Kreider-Letterman; Martin J Baker; Suli Zhang; Neil T Sullivan; Evgeniy Eruslanov; Martin C Abba; Silvia M Goicoechea; Rafael García-Mata; Marcelo G Kazanietz
Journal:  Cell Rep       Date:  2021-11-02       Impact factor: 9.995

Review 7.  Does Axl have potential as a therapeutic target in pancreatic cancer?

Authors:  Wenting Du; Rolf A Brekken
Journal:  Expert Opin Ther Targets       Date:  2018-10-03       Impact factor: 6.902

8.  Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.

Authors:  Carminia Maria Della Corte; Umberto Malapelle; Elena Vigliar; Francesco Pepe; Giancarlo Troncone; Vincenza Ciaramella; Teresa Troiani; Erika Martinelli; Valentina Belli; Fortunato Ciardiello; Floriana Morgillo
Journal:  Oncotarget       Date:  2017-04-04

9.  WNK1 Enhances Migration and Invasion in Breast Cancer Models.

Authors:  Ankita B Jaykumar; Ji-Ung Jung; Pravat Kumar Parida; Tuyen T Dang; Chonlarat Wichaidit; Ashari Rashmi Kannangara; Svetlana Earnest; Elizabeth J Goldsmith; Gray W Pearson; Srinivas Malladi; Melanie H Cobb
Journal:  Mol Cancer Ther       Date:  2021-07-12       Impact factor: 6.009

10.  Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma.

Authors:  Jun Hong; Selma Maacha; Abbes Belkhiri
Journal:  Mol Oncol       Date:  2018-11-05       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.